BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1102 related articles for article (PubMed ID: 36142591)

  • 1. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Na├»ve and Anti-PD-1 Resistant CT26-Bearing Mice.
    Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.
    Chen JS; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Sci Rep; 2022 Jan; 12(1):1100. PubMed ID: 35058524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
    Que Y; Zhang XL; Liu ZX; Zhao JJ; Pan QZ; Wen XZ; Xiao W; Xu BS; Hong DC; Guo TH; Shen LJ; Fan WJ; Chen HY; Weng DS; Xu HR; Zhou PH; Zhang YZ; Niu XH; Zhang X
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
    Bissonnette RP; Cesario RM; Goodenow B; Shojaei F; Gillings M
    BMC Cancer; 2021 Aug; 21(1):969. PubMed ID: 34461854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.
    Suzuki H; Iwamoto H; Tanaka T; Sakaue T; Imamura Y; Masuda A; Nakamura T; Koga H; Hoshida Y; Kawaguchi T
    Hepatol Int; 2024 Apr; 18(2):610-622. PubMed ID: 37864726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
    Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
    Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chidamide and 5-flurouracil show a┬ásynergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
    Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma.
    Chiang IT; Lee YH; Tan ZL; Hsu FT; Tu HF
    Biomed Pharmacother; 2022 Mar; 147():112661. PubMed ID: 35092865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
    Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
    J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.
    Nadal R; Amin A; Geynisman DM; Voss MH; Weinstock M; Doyle J; Zhang Z; Viudez A; Plimack ER; McDermott DF; Motzer R; Rini B; Hammers HJ
    Ann Oncol; 2016 Jul; 27(7):1304-11. PubMed ID: 27059553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models.
    Wang Q; Gao J; Di W; Wu X
    Cancer Immunol Immunother; 2020 Sep; 69(9):1781-1799. PubMed ID: 32347357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
    Christmas BJ; Rafie CI; Hopkins AC; Scott BA; Ma HS; Cruz KA; Woolman S; Armstrong TD; Connolly RM; Azad NA; Jaffee EM; Roussos Torres ET
    Cancer Immunol Res; 2018 Dec; 6(12):1561-1577. PubMed ID: 30341213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.
    Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W
    Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.
    Shin HS; Choi J; Lee J; Lee SY
    Cancer Res Treat; 2022 Apr; 54(2):458-468. PubMed ID: 34517693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.
    Wang F; Jin Y; Wang M; Luo HY; Fang WJ; Wang YN; Chen YX; Huang RJ; Guan WL; Li JB; Li YH; Wang FH; Hu XH; Zhang YQ; Qiu MZ; Liu LL; Wang ZX; Ren C; Wang DS; Zhang DS; Wang ZQ; Liao WT; Tian L; Zhao Q; Xu RH
    Nat Med; 2024 Apr; 30(4):1035-1043. PubMed ID: 38438735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
    Saeed A; Park R; Sun W
    J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.